Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.
Location: United States, California, San Diego
Employees: 51-200
Phone: +234 904 331 6758
Total raised: $181M
Founded date: 2017
Investors 4
Date | Name | Website |
17.08.2021 | Logos Capi... | logoscapit... |
- | Avalon Bio... | avalonbiov... |
- | RA Capital... | racap.com |
- | OrbiMed | orbimed.co... |
Funding Rounds 2
Date | Series | Amount | Investors |
21.04.2021 | Series B | $125M | Logos Capi... |
03.03.2021 | Series A | $56M | - |
Mentions in press and media 13
Date | Title | Description | Source |
20.03.2024 | Startup Lands $150M for Delicate Dance Between Cancer Cells ... | Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of ... | medcitynew... |
10.08.2021 | Janux Therapeutics : Successful $222.9 million IPO in June b... | -Successful $222.9 million IPO in June brings total funds raised in the quarter to $347.9 million- -... | marketscre... |
21.04.2021 | Stealthy biotech Janux nabs $125M and joins chase to direct ... | The fresh capital, a Series B round of financing, comes four months after Janux revealed its Merck p... | medcitynew... |
20.04.2021 | RA Capital leads $125M for Janux in VC's latest crossover... | Four months ago, only a short list of people had ever heard of Janux Therapeutics. Today, they... | endpts.com... |
20.04.2021 | Janux Therapeutics Closes $125 Million Series B Financing to... | - | orbimed.co... |
20.04.2021 | Janux Therapeutics Closes $125M Series B | SAN DIEGO, CA, Janux Therapeutics today announced the closing of a $125 million Series B financing... | vcnewsdail... |
03.03.2021 | Janux Therapeutics has raised a $56M Series A led by Avalon ... | - | connect.or... |
03.03.2021 | Janux Therapeutics Snags $56M Series A | SAN DIEGO, CA, Janux Therapeutics snags $56M funding in Series A led by Avalon Ventures. >>... | vcnewsdail... |
03.03.2021 | Janux raises $56M to take safer T-cell engagers into the cli... | Janux Therapeutics has raised $56 million to fund development of T-cell engagers (TCEs). The series ... | fiercebiot... |
03.03.2021 | Janux raises $56M to take safer T-cell engagers into the cli... | Janux Therapeutics has raised $56 million to fund development of T-cell engagers (TCEs). The series ... | fiercebiot... |
Show more